Cabaletta Bio (CABA.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Event Tracking

Nov11

H.C. Wainwright analyst reiterates buy rating on Cabaletta Bio

12:01

Cabaletta Bio released FY2025 Q3 earnings on November 10 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.4387 (forecast USD -0.4775)

04:00

Cabaletta Bio released FY2025 9 Months Earnings on November 10 (EST), with actual revenue of USD 0 and EPS of USD -1.8763

04:00

Nov10

Willam Blair Analyst Maintains Buy Rating on CABA Stock

18:57

Oct31

Cantor Fitzgerald Raises Cabaletta Bio Target Price to $30

15:35

Oct29

Cabaletta Bio Updates Pipeline for Autoimmune Disease Treatment

11:07

Schedules & Filings

Schedules

Filings

Nov10

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Net Income -44.87 M, EPS -0.4387

Aug7

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Net Income -45.13 M, EPS -0.7293

May15

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Net Income -35.94 M, EPS -0.7083

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change